FY2024 EPS Estimates for Neurogene Lifted by HC Wainwright

Neurogene Inc. (NASDAQ:NGNE) – Investment analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Neurogene in a report released on Tuesday, November 19th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($4.34) for the year, up from their prior forecast of ($4.42). HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Neurogene’s Q4 2024 earnings at ($1.05) EPS, Q1 2025 earnings at ($0.77) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.19) EPS.

Other equities analysts have also recently issued reports about the company. BMO Capital Markets cut their price objective on Neurogene from $60.00 to $45.00 and set an “outperform” rating for the company in a report on Wednesday. Leerink Partners upped their price objective on Neurogene from $45.00 to $72.00 and gave the stock an “outperform” rating in a report on Tuesday, November 12th. William Blair reiterated an “outperform” rating on shares of Neurogene in a report on Tuesday. Robert W. Baird upped their price objective on Neurogene from $54.00 to $72.00 and gave the stock an “outperform” rating in a report on Tuesday, November 12th. Finally, Stifel Nicolaus boosted their target price on Neurogene from $44.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $60.83.

Neurogene Stock Performance

Neurogene stock opened at $15.59 on Thursday. Neurogene has a 52 week low of $12.49 and a 52 week high of $74.49. The business has a 50-day simple moving average of $45.41 and a 200 day simple moving average of $39.62.

Institutional Trading of Neurogene

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its stake in shares of Neurogene by 2.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 30,317 shares of the company’s stock worth $1,272,000 after buying an additional 741 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Neurogene by 192.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock worth $91,000 after buying an additional 1,429 shares during the last quarter. Quest Partners LLC purchased a new stake in Neurogene during the 2nd quarter valued at $55,000. SG Americas Securities LLC purchased a new stake in Neurogene during the 1st quarter valued at $120,000. Finally, Baker BROS. Advisors LP boosted its stake in Neurogene by 0.6% during the 1st quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company’s stock valued at $23,211,000 after purchasing an additional 2,499 shares during the last quarter. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.